<DOC>
	<DOCNO>NCT00115570</DOCNO>
	<brief_summary>The purpose study determine insulin glulisine ( Apidra ) safe effective rapid act insulin insulin lispro ( Humalog ) child adolescent type 1 diabetes mellitus .</brief_summary>
	<brief_title>Comparison Ability Glulisine With Lispro Control Type 1 Diabetes Mellitus Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<criteria>Girls/boys , 417 year , inclusive ; Girls yet childbearing potential , sexually active , agree use reliable medically accept contraceptive measure study ; Type 1 diabetes mellitus establish medical history : example , limited , clear sign insulinopenia ( polyuria , polydipsia , polyphagia , weight loss , ketonuria , ketoacidosis ) ; glutamic acid decarboxylase ( GAD ) antibody indicative type 1 diabetes measure time study ; require continuous insulin therapy time diagnosis ; Onset diabetes least 1 year prior visit 1 ( V1 ) study ; Uninterrupted insulin therapy least 1 year V1 study ; At V1 , stable insulin regimen either NPH insulin glargine basal insulin willing multiple daily injection insulin ; Glycated hemoglobin V1 ≥ 6.0 ≤11.0 % ; Ability/willingness blood glucose monitoring use sponsorprovided glucometer subject diary . Active proliferative diabetic retinopathy , define application focal panretinal photocoagulation vitrectomy , 6 month V1 , unstable/rapidly progress retinopathy require surgical treatment ( include laser photocoagulation ) study ; Diabetes type 1 diabetes mellitus ; Pregnancy ( positive pregnancy blood test V1 ) breastfeeding ; Pancreatectomized subject ; Subjects pancreas and/or islet cell transplant ; Treatment antidiabetic oral agent time diabetes diagnosis ; Treatment systemic corticosteroid last month V1 ; Subjects pump therapy last 2 month V1 ; Subjects require excessively high dos insulin ( `` resistant '' patient ) , example , limited , subject receive 150 IU per day ; Likelihood need treatment study period drug permit protocol Treatment investigational drug last month V1 ; History primary seizure disorder ; History severe hypoglycemic episode accompany seizure and/or coma diabetic ketoacidosis lead hospitalization , care emergency ward , 3 month prior V1 ; History hypoglycemia unawareness ; History hypersensitivity insulin insulin analogs excipients insulin glulisine formulation excipients study insulin preparation formulation ; Clinically relevant hepatic , neurologic , endocrine , active cancer , major systemic disease make implementation protocol interpretation study result difficult would , opinion investigator , preclude safe participation subject protocol ; History cardiac abnormality and/or cardiovascular disorder ; History drug/alcohol abuse ; Impaired hepatic function show , limited , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) great twice normal upper limit age V1 ; Impaired renal function show , limited , serum creatinine great 1.5 time upper limit age V1 ; Non fast triglyceride level &gt; 500 mg/dL ( 5.7 mmol/L ) V1 ; Parent/legally authorize representative unable understand nature , scope , possible consequence study ; Parent/legally authorize representative unable read/write ; Subjects unlikely comply protocol , e.g . inability/unwillingness participate adequate training , uncooperative attitude , inability return followup visit , unlikelihood completing study ; Children/relatives employee sponsor sponsor representative ; Children relatives investigator , subinvestigator , research assistant , pharmacist , study coordinator staff directly involve conduct protocol ; Subjects previously treat insulin glulisine .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Diabetes , Insulin-Dependent , pediatric , rapid act injection</keyword>
</DOC>